Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals · CIK 0001821825
$13.75
0.00% · live
Updated
$3.58B market value
From Organon & Co.'s FY2025 10-K, filed Feb 24, 2026 · read the filing
Organon & develops and makes medicines. It took in $6.22B last year, which makes it a mid-sized company. Of every dollar it sells, about 3 cents is left as profit.
The financial picture is led by accounting, with profitability worth watching, while growth and debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score 1.20
Recent open-market selling by Drinane Juliana Papa, not under a pre-arranged plan.
$200.3K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Organon & Co.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$864.0M → $187.0M
Profit margin
13.5% → 3.0%
Earnings per share
$3.35 → $0.72
Dividends paid
$297.0M → $88.0M
Measured against FY2024, from the 10-K filed Feb 24, 2026
Deteriorated: -78.4%
$864.0M to $187.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
OGN was unchanged on the latest quote. The average Health Care company tracked here moved +1.66%, and the S&P 500 −1.04%. That is 1.7 points below its sector and 1.0 points above the market.
No filing from OGN and no news item about it appeared in the last 3 days.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 7% a year for the next 10 years. Over the last 6 years it shrank by about 25% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 3 cents of every dollar of sales as profit, earning $187.0M last year.
No. Sales shrank 2.9% last year.
Yes. Clearing its debt would take roughly 11.5 years of cash flow. For every $1 it owes, it owns $1.06 in assets. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 47 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 13% of the cash its operations generated. It has paid in each of the last 5 years.
GoodFigures from the FY2025 annual filing
Last year it earned $187.0M and generated $700.0M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 24, 2026Filing for FY2025 | FY202410-K · Feb 28, 2025Filing for FY2024 | FY202310-K/A · Feb 28, 2025Filing for FY2023 | FY202210-K · Feb 28, 2025Filing for FY2022 | FY202110-K · Feb 27, 2023Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B | −2.9% |
| Cost of revenue | $2.90B | $2.69B | $2.52B | $2.29B | $2.38B | +8.0% |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | $3.92B† | −10.8% |
| Gross marginGross profit ÷ revenueWhat is this? | 53.3% | 58.0% | 59.8% | 62.8% | 62.2% | −4.7 pts |
| Selling, general and administrative | $1.72B | $1.76B | $1.89B | $1.70B | $1.67B | −2.2% |
| Interest expense | $504.0M | $520.0M | $527.0M | $422.0M | $258.0M | −3.1% |
| Income before tax | $425.0M | $807.0M | $673.0M | $1.12B | $1.53B | −47.3% |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B | −78.4% |
| Net marginNet income ÷ revenueWhat is this? | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% | −10.5 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $0.7184 | $3.35 | $4.00 | $3.60 | $5.33 | −78.6% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 11,519 shares
Holds 41,566 shares after this filing.
Had shares withheld to cover taxes — 4,134 shares at $13.62 ($56.3K)
Holds 37,432 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2026
Profit margin −2.2 pts · Cash +89.0% · Profit -25.5% — against Q2 FY2025
Read the filingWrite down why you are following Organon & Co., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 118 subsidiaries named in its 10-K, incorporated across 70 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from OGN's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 24, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 5.0 | 6/9 | 10-K, filed Feb 24, 2026 |
| FY2024 | 7.0 | 6/9 | 10-K, filed Feb 28, 2025 |
| FY2023 | 6.0 | 5/9 | 10-K, filed Feb 26, 2024 |
| FY2022 | 6.0 | 6/9 | 10-K, filed Feb 27, 2023 |
| FY2021 | 6.0 | 5/9 | 10-K, filed Mar 21, 2022 |
| FY2020 | 7.3 | 4/5 | 10-K, filed Mar 21, 2022 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
1.20
In the distress zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.65
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −10.5 pts
13.5% to 3.0%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -78.6%
$3.35 to $0.72Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Changed: -70.4%
$297.0M to $88.0MCritical
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Deteriorated: −4.7 pts
58.0% to 53.3%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: -29.6%
$764.0M to $538.0MSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -10.8%
$3.71B to $3.31BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: -15.0%
$675.0M to $574.0MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: -7.4%
$175.0M to $162.0MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 31, 2026 — read it.
Improved: +89.0%
$599.0M to $1.13BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: -25.5%
$145.0M to $108.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: -26.3%
$0.56 to $0.41Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: −2.2 pts
9.1% to 6.9%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: +1.0%
260.0M to 262.6MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 31, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -26.0%
$146.0M to $108.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −3.1 pts
10.0% to 6.9%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -26.0%
$0.56 to $0.41Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +6.7%
$1.46B to $1.56BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +8.2%
$783.0M to $847.0MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 4% and 9%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 7.3% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 6.4x — investors pay $6.4 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
Sold on the open market — 14,761 shares at $13.57 ($200.3K)
Holds 18,475 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 14,761 shares ($200.3K) on or after .
Shares originally obtained via Restricted Stock Vesting Under a Registered Plan.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Held a shareholder vote
Reported another event
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Profit margin +4.3 pts · Profit +67.8% · Free cash flow +337.2% — against Q1 FY2025
Read the filingPublished results
Read the filingSigned a material agreement · Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Profit margin −10.5 pts · Profit -78.4% · Earnings per share -78.6% — against FY2024
Read the filingReported another event
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Profit margin −12.7 pts · Profit -55.4% · Earnings per share -55.9% — against Q3 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2025
Profit margin −3.0 pts · Profit -25.6% · Gross margin −3.6 pts — against Q2 FY2024
Read the filingQuarterly report for Q1 FY2025
Revenue -6.7% · Profit margin −6.6 pts · Profit -56.7% — against Q1 FY2024
Read the filingAnnual report for FY2024
Profit margin −2.8 pts · Profit -15.5% · Free cash flow +39.4% — against FY2023
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join · Reported another event
Read the filingThe first 40 of 118. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-24. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Yahoo Finance ·
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Yahoo Finance ·
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Yahoo Finance ·
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Yahoo Finance ·
Why Organon (OGN) Is Getting Attention Today
Yahoo Finance ·
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device
Yahoo Finance ·
PhaseV Appoints Biopharma Leaders Klaus Beck and Avi Kulkarni to Scientific Advisory Board to Guide Expansion of AI Conductor
Yahoo Finance ·
Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer
Yahoo Finance ·
The Surprising Pockmarks On Cooper's Earnings That Caused Its Stock To Dive
Yahoo Finance ·
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Yahoo Finance ·
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Yahoo Finance ·
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Yahoo Finance ·
Primary sources and further research